Search the Newsreel

Viking Therapeutics, Inc. Revenue Breakdown – NASDAQ:VKTX

The article provides a title for Viking Therapeutics, Inc. Revenue Breakdown (NASDAQ:VKTX) and indicates that it is a financial page on TradingView. However, the content primarily consists of navigation links, disclaimers, and website feature lists rather than actual revenue breakdown data. It mentions market …

Pliant Therapeutics (PLRX) Gains FDA Fast Track for PLN-101095 Amidst Challenging Valuation

Pliant Therapeutics (PLRX) has received FDA Fast Track designation for its investigational drug PLN-101095, a novel therapy for solid tumors resistant to immune checkpoint inhibitors. Despite this positive regulatory news, the company faces significant valuation challenges with zero revenue and an effectively infinite Price-to-Sales …

TENX Q2 2026 Earnings: Narrower Loss Per Share Fails to Offset Stock Decline - EPS Revision Trend

International Paper (IP) Could Be 8% Undervalued On Its Margin Recovery Narrative

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. International Paper (IP) has drawn investor attention after recent share price moves, with the stock up about 7% over the past month and …

RNAC Reiterated by Wedbush -- Rating Maintained at Outperform

Wedbush analyst Martin Fan has reiterated an 'Outperform' rating for Cartesian Therapeutics Inc (RNAC) with a maintained price target of $38.00, despite the stock being significantly overvalued according to GuruFocus's GF Value™. The company, which is pioneering cell therapy using mRNA technology for autoimmune …

Wedbush Reiterates Outperform Rating for Cartesian Therapeutics (NASDAQ:RNAC)

Wedbush reiterated an "Outperform" rating for Cartesian Therapeutics (NASDAQ:RNAC) with a $38 price target, suggesting a significant upside of 314%. The company has a consensus "Moderate Buy" rating from seven analysts, with an average price target of $32.60. Cartesian Therapeutics recently reported strong quarterly …

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Capricor Therapeutics, Inc. (CAPR)

Bernstein Liebhard LLP has announced a securities fraud class action lawsuit against Capricor Therapeutics, Inc. (CAPR) on behalf of investors who purchased shares between December 17, 2025, and July 6, 2026. The lawsuit alleges that Capricor made false and misleading statements that artificially inflated …

Form 8K Turn Therapeutics Inc For: 18 August By Investing.com

This article announces that Turn Therapeutics Inc. filed a Form 8K for August 18. It is a brief news item from Investing.com, providing basic information about the filing. The article also includes various market data, news headlines, and promotional content common to financial news …

Wolfe Research Begins Coverage on First Tracks Biotherapeutics (NASDAQ:TRAX)

Wolfe Research has initiated coverage on First Tracks Biotherapeutics (NASDAQ:TRAX) with an "outperform" rating and an $83 price target, suggesting a significant upside. This new rating contributes to a generally positive analyst sentiment, with a consensus "Moderate Buy" rating and an average target price …

IOVA Maintained by Mizuho -- Price Target Raised to $11.00

Mizuho has maintained an "Outperform" rating on Iovance Biotherapeutics (IOVA) and raised its price target from $10.00 to $11.00, signaling optimism for the company's future in biotechnology. Despite this positive analyst sentiment, IOVA's GF Score™ of 34/100 and high price-to-sales ratio suggest that investors …

AARDVARK THERAPEUTICS, INC. (AARD) INVESTOR ALERT Investors With Large Losses in Aardvark Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Bernstein Liebhard LLP has filed a securities class action lawsuit against Aardvark Therapeutics, Inc. (NASDAQ: AARD) on behalf of investors who purchased shares following its February 2025 IPO or between February 2025 and May 2026. The lawsuit alleges that Aardvark made false and misleading …

MPLT Q1 2026 Earnings: Clinical-Stage Biotech Reports Wider-Than-Expected Loss of -$1.34 Per Share - Positive Surprise Momentum

TNGX Q1 2026 Earnings: Narrow EPS Miss Reflects Clinical-Stage Investment - Cash Flow Report

Scribe Therapeutics (NASDAQ:SCTX) Now Covered by Analysts at Leerink Partners

Leerink Partners initiated coverage on Scribe Therapeutics (NASDAQ:SCTX) with an "outperform" rating and a $37 price target, suggesting a significant upside. This positive sentiment aligns with other analysts, including Guggenheim and Wells Fargo, contributing to a "Buy" consensus rating and an average target of …

Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy

Akari Therapeutics announced new preclinical data for its TROP2-targeted antibody drug conjugate (ADC) AKTX-101, showing robust anti-tumor activity in urothelial cancer models. The data supports the potential of Akari's novel PH1 RNA spliceosome-modulating payload to overcome resistance seen with existing ADC therapies. Akari plans …

Tango Therapeutics (NASDAQ:TNGX) Given New $68.00 Price Target at HC Wainwright

HC Wainwright has increased its price target for Tango Therapeutics (NASDAQ:TNGX) to $68.00 from $66.00, maintaining a "buy" rating and suggesting a significant upside. This comes despite the company reporting a quarterly loss of $0.37 per share, missing the consensus estimate. Tango Therapeutics currently …

Elicio Therapeutics' (ELTX) "Buy" Rating Reaffirmed at HC Wainwright

HC Wainwright has reaffirmed its "Buy" rating for Elicio Therapeutics (ELTX), with an average analyst price target of $19.75, indicating a "Moderate Buy" consensus. Despite this, ELTX shares opened down 2.3% at $3.02, trading below key moving averages and near its 52-week low. The …

Enliven Therapeutics (NASDAQ:ELVN) Now Covered by Barclays

Barclays has initiated coverage on Enliven Therapeutics (NASDAQ:ELVN) with an "overweight" rating and a $78 price target, suggesting a potential upside of 31.03%. This comes amidst mixed analyst sentiment, with a consensus "Moderate Buy" rating and an average target price of $75. The company …

VKTX Stock Draws Fresh Attention Ahead Of Earnings: Wall Street Sees Over 170% Upside As GLP-1 Race Burns Hot

Odyssey Therapeutics Hits $900M Valuation In Nasdaq Debut, Stock Climbs 13% Before Diving Lower

Gain Therapeutics (GANX) Falls 3.8% to $2.04, Testing Support at $1.94 - Charm Flow

Amentum Joint Venture Selected for Australia Nuclear Submarine Shipyard Program

CHANTILLY, Va., August 18, 2026--(BUSINESS WIRE)--Australian Naval Infrastructure (ANI) selected a joint venture between Amentum (NYSE: AMTM) and Laing O'Rourke as its Capability Partner to support the delivery of a nuclear-powered submarine construction yard in South Australia. Under a long-term contract, Amentum and Laing …

RNTX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $8.00

HC Wainwright & Co. has reiterated its 'Buy' rating for Rein Therapeutics (RNTX), maintaining a price target of $8.00. Despite the stock trading significantly below this target at $0.849, the company faces financial weaknesses, particularly in profitability, as indicated by its GF Score™ of …

Rein Therapeutics (NASDAQ:RNTX) Given "Buy" Rating at HC Wainwright

HC Wainwright has reaffirmed its "Buy" rating for Rein Therapeutics (NASDAQ:RNTX), while the broader analyst consensus remains "Hold" with an average price target of $6.00. The clinical-stage biotechnology company is developing RT-101, an early-phase immuno-oncology therapy for solid tumors, and recently reported a quarterly …

INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces

Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) for alleged securities law violations between December 17, 2025, and July 26, 2026. Investors who suffered substantial losses during this period have until September 28, 2026, …

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors

Pliant Therapeutics announced that the FDA has granted Fast Track designation for its drug candidate, PLN-101095, in combination with pembrolizumab. This designation is for treating solid tumors resistant to immune checkpoint inhibitors (ICIs). The Fast Track status aims to expedite the development and review …

Equities Analysts Set Expectations for PRQR FY2030 Earnings

HC Wainwright has updated its FY2030 earnings per share estimate for ProQR Therapeutics (NASDAQ:PRQR) to $0.20, an increase from $0.18, and reiterated a "Buy" rating. Despite this positive revision, the consensus full-year earnings estimate remains a loss of $0.52 per share. The biopharmaceutical company …

HC Wainwright Has Bullish Forecast for FDMT FY2027 Earnings

Tenaya Therapeutics (TNYA) Falls 3.85% to $0.70 as Shares Approach Critical Support - Synthetic Long

Definium Therapeutics (NASDAQ:DFTX) Coverage Initiated by Analysts at Bank of America

Bank of America has initiated coverage of Definium Therapeutics (NASDAQ:DFTX) with a "buy" rating and a $75 price target, indicating a potential 65.71% upside. This positive outlook aligns with other analysts, who collectively give the company an average "Buy" rating and a $63.00 price …

Q3 EPS Estimate for MiNK Therapeutics Boosted by Analyst

HC Wainwright has increased its Q3 2026 EPS estimate for MiNK Therapeutics (NASDAQ: INKT) to a loss of $0.35 per share, up from a previous estimate of $0.63, while maintaining a "Buy" rating and a $35 price target. This adjustment comes after MiNK Therapeutics …

H.C. Wainwright raises Tango Therapeutics price target to $68 By Investing.com

H.C. Wainwright has increased its price target for Tango Therapeutics Inc. (NASDAQ:TNGX) shares to $68 from $66, maintaining a Buy rating. This adjustment follows the company's Q2 2026 results, which showed a higher net loss than previously estimated, but also revealed a strong cash …

Elicio Therapeutics stock price target reiterated at $23 by H.C. Wainwright

H.C. Wainwright has reiterated a Buy rating and a $23 price target for Elicio Therapeutics (NASDAQ:ELTX) after the company reported its second-quarter 2026 results. Despite a significant stock price drop, analyst consensus remains at Strong Buy, and the company has secured $15 million in …

Jasper Therapeutics stock rating reiterated at Buy by H.C. Wainwright

Atrium Therapeutics (RNA) Inches Higher: 0.93% Gain Reinforces Support Zone - Dark Pool Sentiment

HC Wainwright Analysts Lift Earnings Estimates for GALT